Background and Purpose-Guidelines advocate anticoagulant treatment to all patients with atrial fibrillation and concomitant diabetes mellitus. The potential refinement to thromboembolic risk stratification that may spring from subdividing diabetes mellitus is unexplored. The purpose was to investigate duration of diabetes mellitus as a predictor of thromboembolism and anticoagulant-related bleeding in patients with atrial fibrillation. Methods-Using nationwide Danish registries, we identified all patients discharged from hospital with an incident diagnosis of atrial fibrillation from 2000 to 2011. Hazard ratios with 95% confidence intervals for thromboembolism and bleeding according to years of diabetes mellitus duration in categories (0-4, 5-9, 10-14, and ≥15) and as a continuous variable using cubic splines were calculated by Cox regression. Results-The study population comprised 137 222 patients with atrial fibrillation, of which 12.4% had diabetes mellitus.
A trial fibrillation is the most commonly encountered cardiac arrhythmia and it is reaching epidemic proportions. 1 It is a frequent cause of thromboembolic events, such as ischemic stroke. 2 The cause of atrial fibrillation is multifactorial. One important contributor to the increasingly higher prevalence of atrial fibrillation is diabetes mellitus, as the prevalence of diabetes mellitus has risen in the general population. 3, 4 The confluence of diabetes mellitus and atrial fibrillation infers that ≈1 in 5 patients with atrial fibrillation have concurrent diabetes mellitus. 5 Furthermore, in patients with atrial fibrillation, diabetes mellitus is a risk factor for thromboembolic events. 6, 7 International guidelines for management of patients with atrial fibrillation recommend using the CHA 2 DS 2 -VASc score (congestive heart failure, hypertension, age, diabetes mellitus, stroke [doubled] , vascular disease, age, and sex category [female]) 6 to identify patients at sufficiently low risk to be in need of no antithrombotic treatment, whereas all others with 1 risk factor from the score should be considered for oral anticoagulant therapy, except women where female sex is their only risk factor. 8, 9 Because diabetes mellitus is a component in the CHA 2 DS 2 -VASc score, this risk factor-based approach means that all patients with diabetes mellitus should be considered for anticoagulant treatment. Despite these clear recommendations, a widespread underuse of anticoagulant treatment is reported, which underlines a need for a continuous advancement into the epidemiology of thromboembolic risk in patients with atrial fibrillation.
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There is a paucity of research investigating the potential benefit that may spring from subdividing diabetes mellitus in relation to thromboembolic risk stratification in patients with atrial fibrillation. Patients who have had diabetes mellitus for a long period of time have a heavier burden of diabetic complications such as vascular disease, ischemic stroke, autonomic neuropathy, and retinopathy than newly diagnosed patients. 11, 12 These complications have been associated with stroke risk beyond the risk encompassed by diabetes mellitus itself, [12] [13] [14] [15] [16] as well as with episodes of atrial fibrillation. 17 The aim of this cohort study was to investigate the duration of diabetes mellitus and the risk of thromboembolic events in patients with an incident hospital-based diagnosis of atrial fibrillation. Given the association between diabetes mellitus duration and diabetic complications, we hypothesized that longer duration of diabetes mellitus would serve as an important predictive marker of higher thromboembolic risk in the setting of atrial fibrillation.
Materials and Methods

Study Design and Data Sources
The study was designed as a nationwide, register-based cohort study. The unique national identification number given to all Danish residents was used to link individual-level data from several nationwide Danish registries. 18 Data were obtained from 3 registries, such as the Civil Registration System, the National Patient Register, and the National Prescription Registry. [19] [20] [21] In Denmark, the International Classification of Diseases (ICD)-Eigth Revision was used until 1994 and hereafter replaced by ICD-10. For all extracted variables, both primary and secondary diagnoses were obtained. The National Prescription Registry holds individual-level information on all claimed prescriptions from Danish pharmacies since 1995. Information about emigration or death was available from the National Civil Registration system. 19 All ICD codes and Anatomical Therapeutic Chemical (ATC) Classification System drug codes used in this study are available in Table I in the online-only Data Supplement.
Study Population
The study population consisted of all inpatients and outpatients discharged from hospital with an incident diagnosis of nonvalvular atrial fibrillation from 2000 through 2011 as registered in the National Patient Register. 22 Incident cases of atrial fibrillation not habitually residing in Denmark were excluded, as were patients with a previous diagnosis of cancer and patients who died or were diagnosed with thromboembolism or transient ischemic attack on the day of admission ( Figure 1 ).
Exposure Variable
Diabetes mellitus was identified using ICD codes or a claimed prescription of a glucose-lowering drug. 23 Duration of diabetes mellitus was calculated from first diagnosis with an ICD code, or from the first claimed prescription of a glucose-lowering drug, whichever came first, until the time of discharge with a diagnosis of atrial fibrillation.
Outcomes
The primary outcome was thromboembolism, defined as a diagnosis of stroke (ischemic or unspecified, as the majority of unspecified strokes are of ischemic origin 24 ) or systemic arterial embolism in the National Patient Register. 25 All-cause mortality and the combined end point of thromboembolism or death were considered secondary outcomes. Risk of bleeding during treatment with a vitamin K antagonist was also investigated in the subset of patients using vitamin K antagonists at baseline. Bleeding was defined as the occurrence of an intracranial, gastrointestinal, urinary tract, or airway bleeding (see Table I in the online-only Data Supplement for ICD codes).
Covariates
Components of the CHA 2 DS 2 -VASc score, the current guidelinerecommended thromboembolic risk score, 8, 9 were defined at the time of atrial fibrillation diagnosis using a combination of ICD and ATC codes. This included information about heart failure, hypertension, vascular disease, previous ischemic stroke, systemic arterial embolism, and transient ischemic attack. Age was determined from the Civil Registration System. 19 Components of a slightly modified HAS-BLED score, the current guideline-recommended bleeding risk score, 8, 9 were likewise identified using a combination of ICD and ATC codes. 26 This included information about hypertension, abnormal renal/liver function, previous stroke, bleeding history/predisposition, age (>65 years), and drugs/alcohol concomitantly (information about control of blood pressure and time in therapeutic range was not available from the registries). Individual-level information about anticoagulant treatment during the entire follow-up period was available from the National Prescription Registry 21 (see Supplemental Table I in the online-only Data Supplement for ICD and ATC codes).
Statistical Analyses
Incidence rates for thromboembolism, death, and bleeding were calculated according to status of diabetes mellitus duration. Duration of diabetes mellitus was arbitrarily divided into the following categories: 0 to 4 years, 5 to 9 years, 10 to 14 years, and ≥15 years, and also analyzed as a continuous variable modeled as a natural cubic spline with knots at 5, 10, 15, and 20 years of duration, and presented graphically along with the best-fitted straight line. Associations between exposure and risk of outcome were analyzed using Cox proportional regression with time since atrial fibrillation as the underlying time scale. The associations between duration of diabetes mellitus and risk of thromboembolism and death are reported at 5-year follow-up as crude values and, to assess the potential refinement to current thromboembolic risk stratification strategies, also after adjustment for use of oral anticoagulants modeled as a time-varying covariate and components of the CHA 2 DS 2 -VASc risk score. Age was modeled as a continuous covariate using a natural cubic spline. End of follow-up (June 30, 2013) or emigration was considered as outcome-independent censoring. Death was considered a censoring event for the primary outcome, thromboembolism, and the secondary outcome, bleeding. The risk of bleeding was analyzed using only patients who were treated with a vitamin K antagonist at the time of discharge from hospital, or who were initiated on such treatment within 30 days after discharge. All such patients were considered baseline users of vitamin K antagonists. In the bleeding analysis, patients were censored at first occurrence of death, emigration or cessation of oral anticoagulant therapy, and adjustment was made for components of the HAS-BLED score 
Results
We identified 174 182 patients discharged from a Danish hospital with an incident diagnosis of atrial fibrillation from 2000 through 2011. Of those, 36 960 patients were excluded, the majority because of a previous diagnosis of cancer (n=24 051) or from dying or because they suffered a thromboembolic event on the day of admission (n=7961; Figure 1 ). The patients' baseline characteristics are presented in Table 1 . In this cohort, 17 018 patients (12.4%) were classified as having diabetes mellitus. At the time of discharge from hospital, 85% of those where identified using an ICD code, 15% using an ATC code only, and 66% had both an ICD code and a history of claimed glucose-lowering drug prescription.
A history of congestive heart failure, hypertension, ischemic stroke, peripheral artery disease, myocardial infarction, and bleeding was more frequent among patients with diabetes mellitus than patients without diabetes mellitus. Among patients with diabetes mellitus, longer duration of diabetes mellitus was associated with a progressively higher baseline prevalence of these comorbidities. The median available follow-up time was 4.0 years.
Crude incidence rates per 100 person-years are shown in Table II in the online-only Data Supplement. Patients with diabetes mellitus had higher rates of both thromboembolism and death than patients with nondiabetes, and displayed a trend of higher rates with longer duration. Table 2 shows hazard ratios (HRs) for risk of thromboembolism and death using patients without diabetes as mellitus reference after 5 years of follow-up. When categorizing duration of diabetes mellitus, patients with diabetes mellitus with Table 1 Figure 2 shows the HRs associated with duration of diabetes mellitus modeled as continuous variable using a cubic spline for the outcomes of thromboembolism and death after adjustment for anticoagulant treatment and components of the CHA 2 DS 2 -VASc score. Patients with atrial fibrillation but without diabetes mellitus were used as reference. These analyses confirmed an approximately linear dose-response relationship between the duration of diabetes mellitus and the risk of thromboembolism and death. In the linear model, a 5-year increase in duration of diabetes mellitus was associated with an adjusted HR for thromboembolism of 1.06; 95% CI, 1.02 to 1.10.
In an analysis restricted to patients using vitamin K antagonist at baseline, diabetes mellitus was associated with a crude HR for bleeding of 1.23 (95% CI, 1.03-1.48). The association attenuated after adjustment for components of the HAS-BLED bleeding risk score (HR, 1.06; 95% CI, 0.88-1.28). Figure 3 shows that longer duration of diabetes mellitus was not associated with a higher risk of bleeding both before and after adjustment for components of the HAS-BLED bleeding risk score, when compared with patients with atrial fibrillation but without diabetes mellitus. Incidence rates and HRs for bleeding according to categories of diabetes mellitus duration are shown in Table III in the online-only Data Supplement.
All associations about thromboembolism, death, and bleeding were fundamentally unchanged when including patients with a previous diagnosis of cancer and also when limiting the identification of patients with diabetes mellitus and the calculation of duration of diabetes mellitus to be based on ICD codes only (data not shown).
Discussion
In this cohort study, we investigated the potential for refining risk stratification in patients with an incident diagnosis of atrial fibrillation using duration of diabetes mellitus as a predictive marker of risk. Compared with patients without diabetes mellitus, we found that patients with diabetes mellitus were at higher risk of thromboembolism and death, and that longer duration of diabetes mellitus was associated with a progressively higher risk of thromboembolic events, also after careful adjustment for age and remaining components of the guideline-recommended CHA 2 DS 2 -VASc score. Longer duration of diabetes mellitus was not associated with a higher risk of bleeding in patients treated with a vitamin K antagonist.
Strengths and Limitations
The large sample size curtailed the risk of random error. We relied on hospital diagnoses to identify patients with atrial fibrillation, but the validity of this register-based diagnosis is high. 22 Similarly, the positive predictive value of a first diagnosis of diabetes mellitus is high (>95%). 23 We restricted our follow-up period to 5 years, as duration of diabetes mellitus inherently increases during follow-up. The use of nationwide administrative registries to identify outcomes allowed for virtually complete follow-up. Duration of diabetes mellitus was associated with both thromboembolism and death. Censoring by death from causes other than thromboembolism may, therefore, have caused a slight underestimation of the association between diabetes mellitus duration and risk of thromboembolism. Hence, selection bias is not a likely explanation for the study results. The positive predictive value of a diagnosis of stroke from the Danish National Patient Register is high (≈80%), and, more importantly, it is most likely not associated with duration of diabetes mellitus. 25 The study results are, therefore, most likely not attributable to information bias. However, the use of only administrative registries to identify the covariates may have underestimated the prevalence of the comorbidities.
Diabetes mellitus may be involved in the pathogenesis of atrial fibrillation. 3 As a consequence, patients with diabetes mellitus may have atrial fibrillation because of different reasons than patients without diabetes mellitus. We made adjustment for components of the CHA 2 DS 2 -VASc score to unveil the potential refinement made by adding information about diabetes mellitus duration to the currently guidelinerecommended risk stratification strategy (which suggests using the CHA 2 DS 2 -VASc score). 8, 9 The focus was on duration of diabetes mellitus as a risk predictor, not a potential cause. Confounding by other causes of atrial fibrillation and simultaneously possible stroke risk factors is, therefore, not an issue of concern in this study.
Patients with diabetes mellitus without a hospital-based diagnosis of diabetes mellitus and treated only nonpharmacologically were not identified in this study, but the inclusion of some patients with diabetes mellitus in the nondiabetes reference group would only draw the association against the null. Moreover, the hospitalization-based identification of the study population assured that all patients with diabetes mellitus potentially could have obtained a diagnosis in the National Patient Register.
To eliminate the impact of the strong and inherent association between diabetes mellitus duration and age, we chose to model age as a continuous variable despite age being arbitrarily categorized in the CHA 2 DS 2 -VASc and HAS-BLED scores.
We calculated the duration of diabetes mellitus as the time since diagnosis. Actual onset of disease in type 2 diabetes mellitus occurs years before the clinical diagnosis, 27 so this study essentially investigates the potential, predictive value of using time since diagnosis of diabetes mellitus to refine risk stratification in patients with atrial fibrillation. Nonetheless, the delay in diagnosing type 2 diabetes mellitus is most likely universal, and does therefore in all probability not detract from the generalizability of the study results.
Interpretation and Clinical Perspective
In this study, patients with diabetes mellitus were at higher risk of thromboembolic events than patients without diabetes mellitus, and most importantly, the risk was higher the longer the duration of the disease.
A meta-analysis of studies reporting risk predictors for stroke in patients with atrial fibrillation found a higher risk associated with diabetes mellitus. 7 These findings have been supplemented by other large, register-based studies, which have confirmed the role of diabetes mellitus as a risk predictor. 28, 29 Diabetes mellitus is also included in the widely recommended CHA 2 DS 2 -VASc risk stratification tool. 6 No studies have investigated the duration of diabetes mellitus and the risk of thromboembolic events in patients with incident atrial 
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August 2015 fibrillation. However, a population-based study of patients with diabetes mellitus found a dose-response relationship between the duration of diabetes mellitus and the risk of incident ischemic stroke. 12 In addition, duration of diabetes mellitus has been associated with cardiovascular diseases, such as coronary heart disease, 30 left ventricular diastolic dysfunction, 31 and cardiovascular mortality. 32 Although this study explores risk prediction and not causality, some potential factors explaining the association between diabetes mellitus duration and thromboembolic events deserve mention. Longer duration of diabetes mellitus infers a higher burden of diabetic complications. One potential mediator is vascular disease, but this is already encompassed in the CHA 2 DS 2 -VASc score and, therefore, controlled for in our analysis. The persisting association may, therefore, be partly explained by diabetic complications, such as autonomic neuropathy, retinopathy, and nephropathy; all complications that have been associated with risk of stroke beyond the risk encompassed by diabetes mellitus itself. 13, 15, 16 Furthermore, autonomic neuropathy may induce additional episodes of atrial fibrillation, 17 thus influencing the subtype of atrial fibrillation, a factor also important for determining stroke risk in patients with atrial fibrillation. 33 The balance between preventing thromboembolism and avoiding anticoagulation-related bleeding in patients with atrial fibrillation is critical. Despite clear recommendations for initiation of oral anticoagulant therapy, a worldwide pattern of underuse is reported. 10 Patient preferences are an important determinant of whether to treat, and formal thromboembolic and bleeding risk assessment is crucial to guide patients toward the most beneficial line of treatment. 34 The results from previous studies of diabetes mellitus as a bleeding risk predictor are inconsistent. 35, 36 In this study, among patients receiving treatment with a vitamin K antagonist, no clear association between diabetes mellitus and bleeding risk was observed before nor after adjustment for components of the HAS-BLED score, a widely recommended bleeding risk score not including diabetes mellitus. 9, 26 We even found indications of a lower bleeding risk with longer duration of diabetes mellitus. We are unable to provide any plausible explanations for this observation, but a study of patients with type 1 diabetes mellitus (patients with early debut of diabetes mellitus and, therefore, with longer duration of their disease in this study) found duration of diabetes mellitus to be a risk predictor for ischemic stroke, but not hemorrhagic stroke. 37 Considering some limitations of the present bleeding analysis (few bleeding events in the longer duration category, and use of claimed prescriptions and not actual verified usage of vitamin K antagonists to identify treatment periods, making it impossible to evaluate the impact of noncompliance), further studies investigating this matter are needed. However, these results suggest that when considering commencement of anticoagulant treatment, special emphasis may be directed toward patients with longer duration of diabetes mellitus. Of note, whether similar bleeding associations hold true for the nonvitamin K oral anticoagulants is unknown.
Suggestions for Future Research
Subsequent studies should explore whether the association between diabetes mellitus duration and the risk of thromboembolic events is mediated by specific diabetic complications. 38 Also, the potential impact of differentiating between degree of glycemic control as well as subtypes of diabetes mellitus (type 1 versus type 2) calls for investigation. As the Danish population is predominantly white, these findings also need confirmation in populations of different ethnicities.
Summary
In patients with atrial fibrillation, patients with diabetes mellitus with a longer duration of diabetes mellitus had a higher risk of thromboembolic events than patients with diabetes mellitus and shorter diabetes duration. Longer duration of diabetes mellitus was not associated with a risk of bleeding in patients treated with vitamin K antagonists. Considering the critical balance between prevention of thromboembolic events and avoidance of bleeding complications, longer duration of diabetes mellitus may favor initiation of anticoagulant treatment. 
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